Article

Resistance to Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: Genetic and Immune Determinants and Implications for Treatment Sequencing — A Case Series

2026-07-01

Abstract excerpt

<h4>Background: </h4> /Objectives: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy has been the standard of care for muscle-invasive bladder cancer (MIBC) for two decades, yet a substantial proportion of patients derive no benefit. With antibody–drug conjugates and immune checkpoint inhibitors now reshaping the treatment landscape, characterising the determinants of platinum resistanc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 54eb6d85-06fe-58d2-8192-5df841f5f554
DOI: 10.20944/preprints202607.0057.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Resistance to Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: Genetic and Immune Determinants and Implications for Treatment Sequencing — A Case SeriesDOI 10.20944/preprints202607.0057.v1Read

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.Semantic proximity Read

Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis.Semantic proximity Read

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.Semantic proximity Read

A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report.Semantic proximity Read

Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer.Semantic proximity Read

Cell-free urine- and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle invasive bladder cancerSemantic proximity Read

RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.Semantic proximity Read

Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder CancerSemantic proximity Read

Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/DocetaxelSemantic proximity Read

Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysisSemantic proximity Read

Tumor Immune Infiltration as a Predictor of Response to Neoadjuvant Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: An Integrative TCGA AnalysisSemantic proximity Read